Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.
2.

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.

Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW.

Int J Chron Obstruct Pulmon Dis. 2010 Dec 31;6:13-22. doi: 10.2147/COPD.S15455.

4.

Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients.

Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, Sampalis JS.

Curr Med Res Opin. 2014 Jul;30(7):1427-36. doi: 10.1185/03007995.2014.908828. Epub 2014 Apr 14.

PMID:
24666181
5.

Clinical and economic outcomes in an observational study of COPD maintenance therapies: multivariable regression versus propensity score matching.

Roberts MH, Dalal AA.

Int J Chron Obstruct Pulmon Dis. 2012;7:221-33. doi: 10.2147/COPD.S27569. Epub 2012 Mar 22.

6.

Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD.

Dalal AA, Shah MB, D'Souza AO, Lunacsek OE, Nagar SP, Crater GD.

Respir Res. 2012 May 31;13:41. doi: 10.1186/1465-9921-13-41.

7.

Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy.

Dalal AA, Shah M, D'Souza AO, Crater GD.

Respir Med. 2012 Jun;106(6):829-37. doi: 10.1016/j.rmed.2011.11.012. Epub 2012 Mar 17.

9.

Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.

Dalal AA, St Charles M, Petersen HV, Roberts MH, Blanchette CM, Manavi-Zieverink K.

Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:179-87.

10.

Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.

Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD; Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group.

Respir Med. 2012 Mar;106(3):382-9. doi: 10.1016/j.rmed.2011.09.004. Epub 2011 Oct 4.

12.

Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population.

Dalal AA, Shah M, D'Souza AO, Chaudhari S, Crater G.

Int J Chron Obstruct Pulmon Dis. 2012;7:11-9. doi: 10.2147/COPD.S27846. Epub 2012 Jan 18.

13.

Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.

Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.

Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29.

14.

Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.

Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.

J Med Econ. 2011;14(6):769-76. doi: 10.3111/13696998.2011.622817. Epub 2011 Sep 27.

PMID:
21942463
15.

Is salmeterol/fluticasone propionate equivalent to tiotropium bromide in the treatment of COPD?

Gillissen A.

Am J Respir Crit Care Med. 2008 Jul 1;178(1):105; author reply 106-7. No abstract available.

PMID:
18565963
16.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
17.

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.

Thorax. 2008 Jul;63(7):592-8. doi: 10.1136/thx.2007.087213. Epub 2008 Feb 1.

PMID:
18245142
18.

A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.

Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M.

Pulm Pharmacol Ther. 2007;20(5):556-61. Epub 2006 Jul 7.

PMID:
16914336
19.

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Chong J, Karner C, Poole P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009157. doi: 10.1002/14651858.CD009157.pub2. Review.

PMID:
22972134
20.

Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis.

Liu Y, Shi H, Sun X, Zhang D, Zhang Y, Yang K, Mi L, Li M.

Eur J Intern Med. 2014 Jun;25(5):491-5. doi: 10.1016/j.ejim.2014.04.007. Epub 2014 May 10.

PMID:
24816076

Supplemental Content

Support Center